RxDoctor Payments Data

Edward Reis, MD

Internal Medicine · Philadelphia, PANPI 1578597043

Payments from drug & device makers

$622in general payments, 2019–2025

Across 30 payments — averaging $20.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$161
  • GSK$135
  • AbbVie$84
  • Philips North America LLC$80
  • AstraZeneca$43
  • Viiv Healthcare Company$34
  • plus $85 from 4 others

What the payments were for

  • Food & beverage$622100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$622 in reported general payments places this provider in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$85,670
Medicare patients
245
Services billed
773

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin42$46,505
EliquisApixaban24$33,863
JanuviaSitagliptin Phosphate23$23,843
Atorvastatin Calcium267$3,454
Rosuvastatin Calcium113$1,759
Albuterol Sulfate HfaAlbuterol Sulfate48$1,465
Tamsulosin Hcl69$1,446
Levothyroxine Sodium155$1,416
Gabapentin58$1,317
Amlodipine Besylate156$1,237
Ezetimibe19$1,191
Losartan Potassium90$1,003
Metoprolol Succinate62$959
Omeprazole58$926
Pantoprazole Sodium42$843

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$26$46,50542 claims
MerckJanuvia$161$23,84323 claims
AbbVieSynthroid$84$59619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →